A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.
Cost-effectiveness comparison of two new liver disease drugs informs insurance coverage and treatment guideline decisions.
This pharmacoeconomic model provides the first US cost-effectiveness comparison of semaglutide 2.4 mg and resmetirom (80 mg and 100 mg) versus standard of care for MASH, a liver disease affecting millions of Americans. The analysis directly informs payer coverage decisions and clinical practice guidelines for two recently approved MASH therapies.
What the study was
- Study design
- Pharmacoeconomic cost-effectiveness model
- Population
- US adults with metabolic dysfunction-associated steatohepatitis (MASH/NASH)
- Category
- Public Health
- Maturity
- Validated
- Journal
- PharmacoEconomics
Why it surfaced
First cost-effectiveness comparison of the two newly approved MASH drugs. Directly relevant for formulary decisions and guideline development. Published in PharmacoEconomics.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.